New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model
- Keith Limbach1, 2,
- Maureen Stefaniak1, 2,
- Ping Chen3,
- Noelle B. Patterson1, 2,
- Grant Liao3,
- Shaojie Weng3,
- Svetlana Krepkiy3,
- Greg Ekberg3,
- Holly Torano3,
- Damodar Ettyreddy3,
- Kalpana Gowda1,
- Sharvari Sonawane1, 2,
- Arnel Belmonte1, 2,
- Esteban Abot1, 2,
- Martha Sedegah1,
- Michael R. Hollingdale1, 2,
- Ann Moormann4,
- John Vulule5,
- Eileen Villasante1,
- Thomas L. Richie1,
- Douglas E. Brough3 and
- Joseph T. Bruder3Email author
© The Author(s) 2017
Received: 25 April 2017
Accepted: 26 June 2017
Published: 3 July 2017
A DNA-human Ad5 (HuAd5) prime-boost malaria vaccine has been shown to protect volunteers against a controlled human malaria infection. The potency of this vaccine, however, appeared to be affected by the presence of pre-existing immunity against the HuAd5 vector. Since HuAd5 seroprevalence is very high in malaria-endemic areas of the world, HuAd5 may not be the most appropriate malaria vaccine vector. This report describes the evaluation of the seroprevalence, immunogenicity and efficacy of three newly identified gorilla adenoviruses, GC44, GC45 and GC46, as potential malaria vaccine vectors.
The seroprevalence of GC44, GC45 and GC46 is very low, and the three vectors are not efficiently neutralized by human sera from Kenya and Ghana, two countries where malaria is endemic. In mice, a single administration of GC44, GC45 and GC46 vectors expressing a murine malaria gene, Plasmodium yoelii circumsporozoite protein (PyCSP), induced robust PyCSP-specific T cell and antibody responses that were at least as high as a comparable HuAd5-PyCSP vector. Efficacy studies in a murine malaria model indicated that a prime-boost regimen with DNA-PyCSP and GC-PyCSP vectors can protect mice against a malaria challenge. Moreover, these studies indicated that a DNA-GC46-PyCSP vaccine regimen was significantly more efficacious than a DNA-HuAd5-PyCSP regimen.
These data suggest that these gorilla-based adenovectors have key performance characteristics for an effective malaria vaccine. The superior performance of GC46 over HuAd5 highlights its potential for clinical development.
KeywordsGenetic Molecular Vaccine Malaria Adenovector Adenovirus Gorilla Non-human primate Single-administration Efficacy
Malaria, HIV1 and TB kill more than four million people every year . Highly effective vaccines against these diseases have proven difficult to develop and are not yet available. Although most licensed vaccines work by inducing efficacious antibody responses , data from numerous preclinical and clinical studies suggest that highly effective vaccines against these three pathogens may need to elicit strong T cell responses [3–9]. Adenovirus vectors are highly effective vaccine platforms for inducing potent CD8+ T cell responses . Therefore, adenovirus vectors represent attractive vaccine platforms for these pathogens.
CD8+ T lymphocytes are important mediators of protective immunity against the malaria liver stage [11–20]. A gene-based vaccine approach was developed based on findings that heterologous prime-boost immunization induces CD8+ T cells and protection against malaria in mice [21–24], non-human primates  and humans [5, 6, 26–31]. Particularly encouraging data were obtained in a clinical study using a DNA prime-human adenovirus serotype 5 (HuAd5) boost regimen expressing two malaria antigens, Plasmodium falciparum circumsporozoite protein (PfCSP) and P. falciparum apical membrane antigen 1 (PfAMA1). In this study, 4 of 15 volunteers were sterilely protected against controlled human malaria infection (CHMI) . CD8+ T cell responses specific for PfAMA1 were associated with protection, and two of the four protected volunteers had the highest frequency of CD8+ T cell responses specific for PfCSP . DNA priming was essential as the HuAd5 vectors alone failed to elicit protection [5, 32].
Although these results are encouraging, they do not meet the preferred product characteristics target of 75% efficacy set forth by the World Health Organization (WHO) . One approach to improve vaccine efficacy is to identify more potent adenovirus vaccine vectors.
One factor that can affect the potency of an adenovirus-based vaccine is pre-existing immunity against the adenovirus vector. HuAd5 is a relatively common human pathogen, with 35–50% seroprevalence in the USA and Europe and 70–95% seroprevalence in malaria-endemic regions of sub-Saharan Africa [34–39]. Pre-existing immunity against HuAd5 can affect the immunogenicity and efficacy of HuAd5-based vaccines, reducing the percentage of responders and the frequency of T cell responses [40–42]. In the DNA-HuAd5 malaria trial, 50% of the volunteers with low (<12) HuAd5 pre-existing neutralizing antibodies (NAb) titres were protected against CHMI, whereas none of the volunteers with high (>500) pre-existing NAb titres were protected . Since the vast majority of malaria-related deaths occur in sub-Saharan Africa, where the HuAd5 seroprevalence is very high, pre-existing HuAd5 immunity could have a dramatic impact on the efficacy of a HuAd5-based malaria vaccine.
A second factor that can affect the potency of an adenovirus-based vaccine is the inherent capacity of specific adenovirus serotypes to induce immune responses to the encoded transgene. Most studies indicate that HuAd5 and chimpanzee adenovirus type 3 (ChAd3) induce very robust transgene-specific immunity and that other leading adenovirus vectors are less immunogenic and less protective in animal models [39, 43–46]. These studies highlight the need for identifying new highly immunogenic adenovirus serotypes with low seroprevalence in human populations for vaccine development.
Three gorilla adenoviruses, GC44, GC45, and GC46, are being developed as vaccine vectors. Although the gorilla adenoviruses are closely related to human species C adenoviruses , they are not efficiently neutralized by human sera. Less than 6% of people living in the United States are seropositive for GC44, GC45 or GC46; and the few individuals who are seropositive have very low NAb titres against these viruses . In this report, the immunogenicity and efficacy of GC44, GC45 and GC46 vectors expressing the P. yoelii circumsporozoite protein (PyCSP) are described. One vector, GC46, was more efficacious than HuAd5 in this murine malaria model, suggesting that GC46 is a strong candidate for further malaria vaccine development.
Adenovirus seroprevalence and neutralizing antibody assay
NAb assays were performed as previously described  . In brief, serum samples from adults residing in the USA (n = 250), Kenya (n = 90) and Ghana (n = 100) were diluted 1:16, incubated with HuAd5, GC44, GC45 and GC46 vectors expressing the firefly luciferase gene for 1 h at room temperature, and then used to infect 5 × 104 A549 cells in triplicate at a multiplicity of infection (MOI) of 2000 virus particle units (pu)/cell. Twenty-four hours post-infection, the cells were lysed with Cell Culture Lysis Buffer (Promega, Madison, WI) and luciferase activity was measured using the Luciferase Assay Reagent System (Promega). Samples that resulted in >90% reduction in luciferase activity compared to the virus-only control were defined as positive for NAb. The positive samples were then diluted from 1:32 to 1:1024 in twofold increments and tested for their capacity to neutralize the same set of vectors. The endpoint titre was defined as the maximum dilution at which the serum sample displayed a 90% reduction in luciferase activity compared to the virus-only control.
DNA and adenovirus vaccine vectors
Plasmid DNA vectors
The DNA-PyCSP vector (VR2516) was generated by cloning the native, full-length PyCSP gene into VR1020 (Vical, San Diego, CA) . This cloning reaction positions the PyCSP gene downstream from a human cytomegalovirus (HCMV) Immediate-Early (IE) promoter and in-frame with a human tissue plasminogen activator (TPA) signal sequence . The DNA Null vector (VR1020) contains a TPA signal sequence, but does not contain a transgene. VR2516 and VR1020 were manufactured to preclinical grade specifications (Premium Research Ready plasmid DNA) by Puresyn, Inc. (Malvern, PA).
The E1-, partial E3-, E4-deleted, replication-incompetent HuAd5-PyCSP vector and the E1-deleted, replication-incompetent GC44-PyCSP, GC45-PyCSP and GC46-PyCSP vectors were generated in ORF6 cells  using a plasmid-based construction system that positions the PyCSP gene in the E1 region downstream from a HCMV IE promoter . The HuAd5-PyCSP, GC44-PyCSP, GC45-PyCSP and GC46-PyCSP vectors express a codon-optimized PyCSP gene in which the PyCSP glycosylphosphatidylinositol (GPI) anchor has been deleted. The HuAd5 Null and GC46 Null vectors do not express a transgene.
Mice and parasites
Six week old female BALB/c mice were purchased from either Harlan Laboratories (Frederick, MD) or the National Cancer Institute (Frederick, MD). Plasmodium yoelii (17XNL non-lethal strain) parasites were maintained by alternating passage in Anopheles stephensi mosquitoes and female CD1 outbred mice.
Female BALB/c mice were injected intramuscularly in the tibialis anterior muscle with 100 µl of vaccine (50 µl in each leg). The DNA vectors were prepared and diluted for immunization in 1× phosphate buffered saline (PBS). The adenovirus vectors were prepared and diluted for immunization in final formulation buffer . In the single-dose immunogenicity study, 6 mice/group were immunized with 1 × 107, 1 × 108 or 1 × 109 pu of HuAd5-PyCSP, GC44-PyCSP, GC45-PyCSP, GC46-PyCSP or HuAd5 Null. Twenty-one days post-immunization, the mice were killed and splenocytes and sera harvested for evaluation of PyCSP-specific T cell and antibody responses.
In protection study 1, 20 mice/group were primed on day 0 with 100 µg of DNA-PyCSP (VR2516) and boosted on day 43 with 1 × 109 pu of HuAd5-PyCSP, GC44-PyCSP, GC45-PyCSP or GC46-PyCSP. On days 38 and 52, the mice were bled and sera prepared for evaluation of PyCSP-specific antibody responses. On day 55, 6 mice/group were killed and splenocytes harvested for evaluation of PyCSP-specific T cell responses. On day 57, 14 mice/group were challenged intravenously in the tail vein with 100 P. yoelii sporozoites isolated from the salivary glands of infected mosquitoes and diluted for challenge in M199 medium containing 5% normal mouse serum. On days 62–71, parasitaemia was evaluated by examining Giemsa-stained thin blood smears. In protection studies 2 and 3, mice were boosted with HuAd5-PyCSP or GC46-PyCSP, but not with GC44-PyCSP or GC45-PyCSP. Otherwise, the experimental design of the three protection studies was similar. Each protection study contained a group of 20 naïve, non-immunized mice and a group of 20 negative control mice that were primed with VR1020 and boosted with GC46 Null. Mice were considered positive if blood stage parasites were observed in any blood smear. To gauge the severity of the challenge, an ID50 was determined by challenging four groups of naïve BALB/c mice (6 mice/group) with four suboptimal doses of P. yoelii sporozoites (33, 11, 3.7 or 1.2 sporozoites). (An ID50, or infectious dose 50, represents the dose of sporozoites required to infect 50% of challenged mice.) From these infectivity control mice, an ID50 for protection studies 1, 2 and 3 was calculated to be 2.45 sporozoites, 3.4 sporozoites and 3.4 sporozoites, respectively.
Single cell splenocyte suspensions were prepared by gently crushing the spleen between a 70 µm cell strainer placed over a 50 ml conical tube and the flat end of a sterile 3 ml syringe plunger while rinsing the cells with cold wash buffer (1× Hank’s Balanced Salt Solution without Ca2+ and Mg2+, with 0.5% FBS and 10 mM HEPES). The cell suspension was washed twice with wash buffer, then the cell pellet was resuspended in 5 ml of Red Blood Cell Lysis Buffer (Sigma-Aldrich, St. Louis, MO). Following a 3 min lysis, wash buffer was added to a final volume of 50 ml. The cell suspension was then pelleted, resuspended in 20 ml of R10 media (RPMI-1640 media with 10% FBS, 1× GlutaMax™-1 Supplement and 1× Penicillin–Streptomycin), passed through a second 70 µm cell strainer into a clean 50 ml conical tube, counted with a Guava PCA (EMD Millipore, Billerica, MA), pelleted and resuspended in R10 media at a final concentration of 1 × 107 cells/ml.
Peptide-pulsed stimulator cells were prepared by pulsing A20.2J (Clone HB-98, ATCC, Manassas, VA) suspension cells (1 × 107 cells/ml) with peptides (20 µg/ml for peptides <10 amino acids and 100 µg/ml for peptides >10 amino acids) for a minimum of 1 h with gentle mixing every 20 min. The peptide-pulsed A20.2J cells were irradiated in a Cobalt-60 irradiator (16,666 rad), washed with R10 media and resuspended in R10 media at a final concentration of 1.35 × 106 cells/ml for the ELISpot assays, or 1.5 × 106 cells/ml for the ICS assays. Additional peptide was added to the cell suspension at a final concentration of 20 µg/ml.
IFN-γ ELISpot responses were assessed with fresh splenocytes in group pools (6 mice/group) in quadruplicate wells. Group pools were prepared by combining splenocytes from the individual mice in equal ratios. Splenocytes were stimulated with A20.2J cells pulsed with peptides encoding the PyCSP immunodominant CD8+ T cell epitope (amino acids 280–288, SYVPSAEQI)  or the PyCSP CD4+ immunodominant/nested CD8+ subdominant T cell epitopes (amino acids 57–70, KIYNRNIVNRLLGD)  (AnaSpec, Fremont, CA). Media alone, splenocytes stimulated with irradiated non-pulsed A20.2J cells and PMA/Ionomycin-stimulated splenocytes served as assay controls. In brief, multiscreen MSHAS4510 plates (EMD Millipore) were coated with 100 µl/well of a rat anti-mouse IFN-γ antibody (Clone R4-6A2, BD Biosciences, San Jose, CA) at a final concentration of 10 µg/ml in 1× PBS, pH 7.2. The plates were washed 3 times with RPMI-1640 media and blocked with R10 media at 37 °C in 5% CO2 for a minimum of 3 h. The blocking media were then removed and the splenocyte group pools were plated at 400,000, 200,000 and 100,000 cells/well with 135,000 peptide-pulsed A20.2J stimulator cells/well. The plates were incubated at 37 °C in 5% CO2 for 40 h and washed 9 times with PBS-T buffer (1× PBS, pH = 7.2 with 0.01% Tween-20). Biotinylated rat anti-mouse IFN-γ antibody (clone XMG1.2, BD Biosciences) at 1 µg/ml in 1× PBS, pH = 7.2 was then added and the plates were incubated for 3 h at room temperature. After 3 washes with PBS-T, the plates were incubated for 1 h at room temperature with a 1:800 dilution of peroxidase-labeled streptavidin (KPL, Gaithersburg, MD) in 1× PBS, pH = 7.2. The plates were then washed 3 times with PBS-T and 3 times with 1× PBS, pH = 7.2. The spots were developed with DAB Reagent Set (KPL) according to the manufacturer’s instructions. The spots were counted using an AID ELISpot Reader (Autoimmun Diagnostika, Strassberg, GER). Data analysis was done with Microsoft Excel 2008 for Mac (Microsoft, Redmond, WA) and GraphPad Prism v5.0c (GraphPad Software, La Jolla, CA).
Flow cytometry: intracellular cytokine (ICS) staining and cell phenotyping
Freshly isolated splenocytes from individual mice (6 mice/group) were stimulated with A20.2J cells pulsed with peptides encoding the PyCSP immunodominant CD8+ T cell epitope (amino acids 280–288, SYVPSAEQI), the PyCSP CD4+ immunodominant/nested CD8+ subdominant T cell epitopes (amino acids 57–70, KIYNRNIVNRLLGD) or the influenza hemagglutinin CD8+ T cell epitope (amino acids 332–340, TGLRNTPSI). Media, splenocytes stimulated with irradiated non-pulsed A20.2J cells and PMA/Ionomycin-stimulated splenocytes served as assay controls. In brief, 1 × 106 splenocytes from individual mice and 1.5 × 105 peptide-pulsed A20.2J stimulator cells were incubated for 6–8 h at 37 °C in 5% CO2 in 96-well round bottom plates. BD Golgi Plug™ (BD Bioscience) was added 1 h into the incubation to block cytokine release. The plates were then wrapped in plastic wrap and stored at 4 °C overnight. The samples were stained for viability using the LIVE/DEAD® Fixable Blue Dead Cell Stain Kit for UV excitation from Molecular Probes® (Life Technologies, Grand Island, NY) and blocked for non-specific staining using Mouse BD Fc Block™ (BD Biosciences). For the single-dose immunogenicity study, the samples were surface-stained with the following antibodies (fluorochrome): CD4—RM4-5(eFlur-450) (eBioscience, San Diego, CA) and CD8a—53-6.7(PerCP-Cy5.5) (BD Biosciences). Following separate fixation and permeabilization steps, the samples were stained intracellularly with the following antibodies (fluorochrome): IFN-γ—XMG1.2(PE), TNF-α—MP6-XT22(APC), and IL-2—JES6-5H4 (Alexa488) (BD Biosciences). The data were acquired using a BD FACSCalibur E1610 equipped with a Cytek DxP Multi-Colour Upgrade (using 3 lasers to allow acquisition of 8 colours) and an Automated Micro-Sampler (96 well format) (BD Biosciences). The samples for the prime-boost experiments were surface-stained with the following antibodies (fluorochrome): CD19—1D3 (APC-H7), CD4—RM4-5(V500) (BD Biosciences), NKp46—29A1.4 (PerCP-e710) (eBioscience San Diego, CA), CD44—IM7(PE-Cy7), CD127—A7R34(BV421) and KLRG1—2F1/KLRG1(APC) (Biolegend, San Diego, CA). Following separate fixation and permeabilization steps, the samples were stained intracellularly with the following fluorochrome-labeled antibodies: CD8a—53-6.7(BV785), TNF-α—MP6-XT22(BV605) (Biolegend), CD3e-500A2 (Alexa 700), IFN-γ—XMG1.2(Alexa 488) and IL-2—JES6-5H4(PE) (BD Biosciences). The data were acquired using a BD LSR II equipped with 4 lasers and the automated 96-well high throughput system (BD Biosciences). Primary data analysis was done with FlowJo v9.5.2 (Tree Star, Ashland, OR). Subsequent data analyses were done with Microsoft Excel 2008 for Mac and GraphPad Prism v5.0c.
In the single-dose immunogenicity study, Immulon 4 HBX flat-bottom microtitre plates (Dynex Technologies, Chantilly, VA) were coated overnight with purified PyCSP protein produced in yeast at a final concentration of 0.1 µg/ml. In the prime-boost protection studies, Immulon 4 HBX plates were coated with a synthetic peptide encoding a portion of the immunodominant PyCSP repeat region (QGPGAP)4 (AnaSpec) at a final concentration of 0.5 µg/ml (0.05 µg/well) in coating buffer (15 mM sodium carbonate, 35 mM sodium bicarbonate in UltraPure Water). The plates were blocked for 2 h with casein blocker in Tris buffered saline (TBS) (Pierce Thermo Scientific, Rockford, IL), washed with 1× TBS with 0.1% Tween-20 and incubated for 2 h at room temperature with threefold serial dilutions of sera from individual mice in triplicate wells. The plates were then washed and incubated for 2 h with a 1:2000 dilution of ReserveAP phosphatase-labeled goat anti-mouse IgG (H + L), human serum absorbed (KPL) in Diluting Buffer (1× TBS with 0.1% BSA, 0.05% Tween-20). The plates were washed and developed with 0.1 mg/well of p-Nitrophenyl phosphate (Sigma-Aldrich) dissolved in Coating Buffer. The reaction was stopped by adding 25 µl/well of stop solution (5 N Sodium Hydroxide). Absorbance was measured at 405 nm using a SpectraMax 190 ELISA reader (Molecular Devices, Sunnyvale, CA) or a SpectraMax 340PC plate reader (Molecular Devices). Data analysis was done with Microsoft Excel 2008 for Mac and GraphPad Prism v5.0c.
Indirect immunofluorescent antibody (IFA)
Sporozoite stage IFAs were performed as previously described  using a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG antibody (KPL). Endpoint dilutions were determined for individual mice, except for the negative control and naïve samples, where group pools were used. Endpoint dilution values represent the average of two separate assays.
Statistical analysis of the single-dose immunogenicity data was performed using one-way analysis of variance (ANOVA) followed by Bonferroni’s mean comparison test with Origin Pro 8.0 (OriginaLab, Northhampton, MA). Statistical analysis of the protection data was performed using a two-tailed Fisher’s Exact Test with GraphPad Prism v5.0c. Statistical analysis of the prime-boost ICS data was performed using a non-parametric, two-tailed, Mann–Whitney U test with GraphPad Prism v5.0c. Statistical analysis of the prime-boost ELISA data was performed using an unpaired, two-tailed t test with GraphPad Prism v5.0c. Statistical analysis of the IFA data was performed using a two-tailed t test with GraphPad Prism v5.0c. P values of less than 0.05 were considered significant.
Seroprevalence of GC44, GC45 and GC46 is low in humans living in Kenya and Ghana
GC44, GC45 and GC46 vectors expressing PyCSP induce robust PyCSP-specific T cell and antibody responses in mice
DNA-GC46 vaccine is more efficacious than DNA-HuAd5 vaccine in the P. yoelii/mouse malaria model
Protected mice/total mice (% protected)
Total vs. Null
Total vs. DNA-HuAd5
In study 1, the efficacy of the DNA-GC44 and DNA-GC46 vaccines was slightly higher than the DNA-HuAd5 vaccine, and much higher than the DNA-GC45 vaccine (Table 1). None of the 14 mice immunized with the DNA and GC46 Null vectors, and none of the 14 naïve mice were protected (Table 1). The protection induced by the DNA-HuAd5 vaccine (p = 0.0407), DNA-GC44 vaccine (p = 0.0159) and DNA-GC46 vaccine (p = 0.0058), but not the DNA-GC45 vaccine (p = 0.4815), was statistically significant compared to the negative controls.
To confirm the higher efficacy of the DNA-GC46 vaccine relative to the DNA-HuAd5 vaccine, two further studies were performed with the DNA-HuAd5 and DNA-GC46 vaccines. In study 2, the efficacy of the DNA-HuAd5 vaccine was lower than in study 1 and was not statistically significant compared to the negative controls (p = 0.4815). In contrast, the efficacy of the DNA-GC46 vaccine was higher than the DNA-HuAd5 vaccine and was statistically significant (p = 0.0407) compared to the negative controls. In study 3, the efficacy of the DNA-HuAd5 vaccine was also low and was not statistically significant (p = 0.2222) compared to the negative controls. The efficacy of the DNA-GC46 vaccine, however, was very high (93% protection) and was highly statistically significant (p < 0.0001) compared to the negative controls.
DNA-GC vaccines induce robust T cell and antibody responses in mice
Further phenotypic and functional analysis of individual animals by ICS confirmed that the primary T cell populations responding to PyCSP 280–288 peptide stimulation were antigen-experienced CD8+ T cells (CD3+/CD8+/CD44+ “bright”) expressing IFN-γ (IFN-γ+/IL-2−/TNF-α−) or IFN-γ and TNF-α (IFN-γ+/IL-2−/TNF-α+) (Fig. 5b). Much lower frequencies of triple positive (IFN-γ+/IL-2+/TNF-α+) and IFN-γ/IL-2 double positive (IFN-γ+/IL-2+/TNF-α−) CD8+ T cells were observed. Overall, the frequency of the observed subsets was comparable in all vaccine groups, except that the DNA-GC46 vaccine induced a robust, but significantly lower frequency of IFN-γ+/IL-2−/TNF-α+ CD8+ T cells than the DNA-HuAd5 vaccine (DNA-GC46: 5.24% ± 2.09%; DNA-HuAd5: 9.42 ± 0.92%; p = 0.0043). Consistent with the IFN-γ ELISpot data, multifunctional T cell analysis indicated that cytokine expression from CD4+ T cells was negligible after stimulation with the PyCSP CD4+ immunodominant epitope (amino acids 57–70) (Additional file 1).
The WHO has estimated that approximately 429,000 people died from malaria in 2015 . Despite decades of effort, a highly effective malaria vaccine is not available. The leading vaccine candidate, RTS,S, has modest efficacy against clinical malaria in children and infants living in Africa [53, 54]. However, after 4 years, efficacy slowly wanes to zero [55, 56]. Based upon these results, new approaches are needed to meet the preferred product characteristics target of 75% efficacy .
Vector-based prime-boost vaccines are a compelling approach for malaria vaccine development. In addition to the positive protection data obtained with the DNA-HuAd5 vaccine candidate , a prime-boost regimen with chimpanzee adenovirus type 63 (ChAd63) and modified vaccinia Ankara (MVA) vectors expressing PfCSP or a P. falciparum thrombospondin-related adhesion protein construct with a multi-epitope (ME) string of 17 P. falciparum B cell and T cell epitopes (PfME-TRAP) protected a total of 1 of 15 or 5 of 29 volunteers, respectively, against CHMI [6, 57]. In a Phase 2b trial, the ChAd63-MVA PfME-TRAP vaccine reduced the risk of malaria infection in Kenyan adults by 67% during the first 8 weeks post-immunization . Although this vaccine does not meet the 75% efficacy target, these results are very encouraging and suggest that a non-human primate adenovirus vector can be a component of an efficacious malaria vaccine.
The major rationale for this study was to develop highly potent adenovectors with low human seroprevalence as an alternative to HuAd5, as high seroprevalence in malaria-endemic countries may compromise the efficacy of a HuAd5-based vaccine. The data presented in this report support the development of three new adenovirus vaccine vectors, GC44, GC45 and GC46. These vectors were isolated from wild gorillas in Rwanda and cluster by phylogeny in the same subgroup (species C adenoviruses) as two other potent vaccine vectors, HuAd5 and ChAd3. The results presented indicate that the seroprevalence of NAb specific for GC44, GC45 and GC46 are low in Kenya and Ghana, two malaria-endemic countries in sub-Saharan Africa. In fact, only 1–3% of adults living in Kenya and Ghana have NAb titres against GC44, GC45 or GC46 that are >200, a titre that has been shown to affect the potency of HuAd5-based vectors in previous clinical trials . Moreover, since the seroprevalence and NAb titres against adenoviruses are lower in children than adults , pre-existing immunity should not affect the potency of GC-based vaccines in pediatric populations.
The superior performance of GC46 over HuAd5 highlights its potential for malaria vaccine development. Efficacy studies in the P. yoelii/mouse model indicated that a prime-boost regimen with DNA-PyCSP and GC-PyCSP vectors could protect mice against a P. yoelii challenge. GC46 was more protective than HuAd5 in three separate experiments and when analysed together, the efficacy of GC46 was significantly higher than HuAd5 (p > 0.0018). Typical of complex biological systems, overall efficacy levels varied between experiments. Results also indicated that the GC-PyCSP vectors are more immunogenic than HuAd5-PyCSP following a single immunization. At the lower doses, the three GC-PyCSP vectors all induced higher CD8+IFN-γ+ T cell responses than HuAd5-PyCSP, and at the highest dose, the three GC-PyCSP vectors all induced higher antibody responses than HuAd5-PyCSP. GC46-PyCSP, in particular, was highly immunogenic, inducing greater T cell and antibody responses than HuAd5-PyCSP at all doses. Similar results were obtained with GC44, GC45 and GC46 vectors expressing respiratory syncytial virus (RSV) , herpes simplex virus 2, Epstein Barr virus, and other malaria antigens (unpublished data). These results highlight the versatility of these new gorilla adenovirus vectors for vaccine development.
Previous studies with DNA and adenovirus-based vaccines in the P. yoelii/mouse model have indicated that protection is dependent on CD8+ T cells [16, 22]. CD8+ T cell responses have also been associated with the protection elicited by the DNA-HuAd5 and ChAd63-MVA malaria vaccines in humans [5, 6]. The GC-PyCSP vectors evaluated in this report all induced robust CD8+ T cell responses after priming with DNA. Phenotypic and multifunctional analysis identified antigen experienced CD8+IFN-γ+ T cells or CD8+IFN-γ+TNF-α+ T cells as the primary cellular subsets responsible for this response. Interestingly, the only significant immunological difference observed between the DNA-HuAd5 and DNA-GC46 regimens was in the frequency of CD8+IFN-γ+TNF-α+ T cells. These analyses suggest that immune parameters other than IFN-expressing CD8+ T cells may be involved in protective immunity. Overall, the DNA-GC46 vaccine induced robust CD8+ IFN-γ+ T cell and antibody responses, as well as consistently significant protection, thereby indicating that GC46 is a compelling alternative to HuAd5 for clinical development.
The capacity of the GC vectors to induce robust and protective immune responses suggests that GC vectors belong to a select group of adenovirus vectors that are at least on par with HuAd5 in terms of potency. These results are encouraging because most adenovirus vectors, with the exception of ChAd3, are less immunogenic than HuAd5 [39, 43–46]. For example, preclinical data demonstrate that a single administration of 1 × 1010 viral particles of a ChAd3-Ebola virus vector protected macaques from Ebola virus challenge . This is similar to what has been observed with a HuAd5-Ebola virus vector . Importantly, none of the other leading adenovectors (human adenovirus serotype 35, human adenovirus serotype 26 or ChAd63) were capable of providing this high-level protection [44, 46]. As a result, ChAd3 is currently being tested in clinical trials as a vaccine vector for Ebola virus and hepatitis C virus (HCV) [60–63].
The low seroprevalence, robust immunogenicity and enhanced efficacy of GC46 vectors relative to HuAd5 vectors suggest that this gorilla-based adenovector has key performance characteristics for an effective malaria vaccine. A DNA-GC46 malaria vaccine may be more efficacious than a DNA-HuAd5 malaria vaccine in humans, especially those individuals with high HuAd5 NAb titres. Additional efficacy, if needed, could potentially be obtained by incorporating new protective antigens into the vaccine [6, 64] or by improving the immunogenicity of the individual DNA or adenovirus vaccine components [65, 66].
KL, JTB designed and led experiments and drafted and finalized the manuscript. KL, JTB, MS, PC, NBP, KG, SS, AB, EA, MS, AM, JV, GL, SW, SK, GE, HT, SK assisted with experimental design, developed protocols, conducted in vitro and in vivo experiments, acquired data, analysed data, created figures, and conducted biostatistical analyses. MRH, DEB provided manuscript oversight and review. JTB, DE, DEB designed and oversaw the construction and certifications of the adenovectors for the study. EV, TLR, DEB, JTB and KL oversaw all aspects of the studies and analysis. All authors were involved in critical review of the manuscript. All authors read and approved the final manuscript.
We would like to thank Randy Osborn, Fouzia Farooq, Dianne Litilit, Joanne Lumsden and Danett Bishop for their excellent technical assistance. We thank Chris Lazarski for expert advice on analysis of T cell responses by flow cytometry and Rena Cohen for copy editing and assistance with submission of the manuscript. The views expressed in this paper are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government. Kalpana Gowda, Martha Sedegah and Eileen Villasante are employees of the US Government. Thomas Richie was a US military officer at the time this work was performed. This work was prepared as part of their official duties. Title 17 USC §105 provides that ‘Copyright protection under this title is not available for any work of the United States Government’. Title 17 USC. §101 defines US Government work as work prepared by a military service member or employee of the US Government as part of that person’s official duties. Ping Chen, Grant Liao, Shaojie Weng, Svetlana Krepkiy, Greg Ekberg, Holly Torano, Damodar Ettyreddy, Douglas Brough and Joseph Bruder are/were employees of GenVec, Inc., a for-profit corporation.
Availability of data and materials
All data generated or analysed during this study are included in this published article and its supplementary information files.
The experiments reported herein were approved by the Walter Reed Army Institute of Research/Naval Medical Research Center Institutional Animal Care and Use Committee and conducted in compliance with the Animal Welfare Act and in accordance with the principles set forth in the “Guide for the Care and Use of Laboratory Animals”, Institute of Laboratory Animals Resources, National Research Council, National Academy Press, 1995.
This work was supported by the Military Infectious Diseases Research Program, Project Numbers F0299_12_NM and F0389_14_NM.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Nabel GJ. Designing tomorrow’s vaccines. N Engl J Med. 2013;368:551–60.View ArticlePubMedPubMed CentralGoogle Scholar
- Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401–9.View ArticlePubMedGoogle Scholar
- Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J, McMurray DN. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One. 2009;4:e5856.View ArticlePubMedPubMed CentralGoogle Scholar
- Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473:523–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS ONE. 2013;8:e55571.View ArticlePubMedPubMed CentralGoogle Scholar
- Ewer KJ, O’Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013;4:2836.View ArticlePubMedPubMed CentralGoogle Scholar
- Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Kim Y, et al. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLoS ONE. 2014;9:e106241.View ArticlePubMedPubMed CentralGoogle Scholar
- Bijker EM, Teirlinck AC, Schats R, van Gemert GJ, van de Vegte-Bolmer M, van Lieshout L, et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites. J Infect Dis. 2014;210:1605–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359–65.View ArticlePubMedGoogle Scholar
- Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003;77:6305–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Weiss WR, Good MF, Hollingdale MR, Miller LH, Berzofsky JA. Genetic control of immunity to Plasmodium yoelii sporozoites. J Immunol. 1989;143:4263–6.PubMedGoogle Scholar
- Hoffman SL, Weiss W, Mellouk S, Sedegah M. Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunol Lett. 1990;25:33–8.View ArticlePubMedGoogle Scholar
- Weiss WR, Jiang CG. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One. 2012;7:e31247.View ArticlePubMedPubMed CentralGoogle Scholar
- Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8+ T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune response. Immunol Rev. 2008;225:272–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Krzych U, Dalai S, Zarling S, Pichugin A. Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol. 2012;3:370.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol. 1997;158:1268–74.PubMedGoogle Scholar
- Schofield L. T cell immunity to malaria sporozoites. Exp Parasitol. 1989;68:357–64.View ArticlePubMedGoogle Scholar
- Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA. 1988;85:573–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Cockburn IA, Amino R, Kelemen RK, Kuo SC, Tse SW, Radtke A, et al. In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages. Proc Natl Acad Sci USA. 2013;110:9090–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Tsuji M. A retrospective evaluation of the role of T cells in the development of malaria vaccine. Exp Parasitol. 2010;126:421–5.View ArticlePubMedGoogle Scholar
- Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 2002;20:1039–45.View ArticlePubMedGoogle Scholar
- Sedegah M, Trevor J, Kaur M, Hedstrom R, Hobart P, Tine J, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA. 1998;95:7648–53.View ArticlePubMedPubMed CentralGoogle Scholar
- Hill AV, Reyes-Sandoval A, O’Hara G, Ewer K, Lawrie A, Goodman A, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin. 2010;6:78–83.View ArticlePubMedGoogle Scholar
- Bruder JT, Semenova E, Chen P, Limbach K, Patterson NB, Stefaniak ME, et al. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS ONE. 2012;7:e33920.View ArticlePubMedPubMed CentralGoogle Scholar
- Jiang G, Shi M, Conteh S, Richie N, Banania G, Geneshan H, et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS ONE. 2009;4:e6559.View ArticlePubMedPubMed CentralGoogle Scholar
- Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 2004;1:e33.View ArticlePubMedPubMed CentralGoogle Scholar
- Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, Lang T, et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1–6 year old children in a malaria endemic area. Vaccine. 2006;24:4709–15.View ArticlePubMedGoogle Scholar
- Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, et al. A human phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine. 2011;29:7514–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O’Hara GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE. 2012;7:e31208.View ArticlePubMedPubMed CentralGoogle Scholar
- Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS ONE. 2013;8:e57726.View ArticlePubMedPubMed CentralGoogle Scholar
- Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA. 2005;102:4836–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Tamminga C. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One. 2011;6:e25868.View ArticlePubMedPubMed CentralGoogle Scholar
- WHO. Preferred product characteristics for malaria vaccines. 2014. Accessed at http://www.who.int/immunization/documents/innovation/WHO_IVB_14.09/en/.
- Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77:8263–71.View ArticlePubMedPubMed CentralGoogle Scholar
- Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11:351–7.PubMedPubMed CentralGoogle Scholar
- Xiang Z, Li Y, Cun A, Yang W, Ellenberg S, Switzer WM, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis. 2006;12:1596–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011;29:5203–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Johnson TR, Rangel D, Graham BS, Brough DE, Gall JG. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther. 2014;22:196–205.View ArticlePubMedGoogle Scholar
- Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013;190:2720–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006;194:1638–49.View ArticlePubMedPubMed CentralGoogle Scholar
- McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case–cohort analysis. Lancet. 2008;372:1894–905.View ArticlePubMedPubMed CentralGoogle Scholar
- Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA. 2012;109:E3503–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81:4654–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85:4222–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4:115ra2.View ArticlePubMedPubMed CentralGoogle Scholar
- Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126–9.PubMedGoogle Scholar
- McVey D, Cranfield MR, Torano H, Kuete HM, Lee GP, Glenn A, et al. Adenoviruses isolated from wild gorillas are closely related to human species C viruses. Virology. 2013;444:119–23.View ArticleGoogle Scholar
- Sedegah M, Brice GT, Rogers WO, Doolan DL, Charoenvit Y, Jones TR, et al. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations. Infect Immun. 2002;70:3493–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector–cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 1996;70:6497–501.PubMedPubMed CentralGoogle Scholar
- Dobano C, McTague A, Sette A, Hoffman SL, Rogers WO, Doolan DL. Mutating the anchor residues associated with MHC binding inhibits and deviates CD8+ T cell mediated protective immunity against malaria. Mol Immunol. 2007;44:2235–48.View ArticlePubMedGoogle Scholar
- Charoenvit Y, Leef MF, Yuan LF, Sedegah M, Beaudoin RL. Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect Immun. 1987;55:604–8.PubMedPubMed CentralGoogle Scholar
- WHO. World Malaria Report Geneva: World Health Organization. 2016; http://www.who.int/malaria/publications/world-malaria-report-2016/report/en/.
- Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863–75.View ArticlePubMedGoogle Scholar
- RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284–95.View ArticleGoogle Scholar
- Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, et al. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013;368:1111–20.View ArticlePubMedPubMed CentralGoogle Scholar
- WHO. Malaria vaccine: WHO position paper. 2016. http://www.who.int/wer/2016/wer9104/en/.
- Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2014;7:1076–86.Google Scholar
- Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med. 2015;7:286re5.View ArticlePubMedPubMed CentralGoogle Scholar
- Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011;17:1128–31.View ArticlePubMedGoogle Scholar
- Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1.View ArticlePubMedPubMed CentralGoogle Scholar
- Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6:261ra153.View ArticlePubMedPubMed CentralGoogle Scholar
- Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, et al. Chimpanzee adenovirus vector ebola vaccine. N Engl J Med. 2017;376:928–38.View ArticlePubMedGoogle Scholar
- Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, et al. A monovalent chimpanzee adenovirus ebola vaccine—preliminary report. N Engl J Med. 2015. doi:10.1056/NEJMoa1411627.PubMedGoogle Scholar
- Limbach K, Aguiar J, Gowda K, Patterson N, Abot E, Sedegah M, et al. Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates. Malar J. 2011;10:65.View ArticlePubMedPubMed CentralGoogle Scholar
- Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol. 2013;4:354.View ArticlePubMedPubMed CentralGoogle Scholar
- Padte NN, Boente-Carrera M, Andrews CD, McManus J, Grasperge BF, Gettie A, et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS ONE. 2013;8:e78407.View ArticlePubMedPubMed CentralGoogle Scholar